Nelotanserin - Axovant Sciences

Drug Profile

Nelotanserin - Axovant Sciences

Alternative Names: APD-125; RVT-102

Latest Information Update: 12 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Axovant Sciences
  • Class Antidementias; Antiparkinsonians; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lewy body disease
  • Discontinued Insomnia

Most Recent Events

  • 08 Jan 2018 Efficacy data from a phase II trial in Lewy body disease released by Axovant Sciences
  • 01 Nov 2017 Axovant Sciences completes a phase II trial in Lewy body disease (In adults, In the elderly) in USA (PO) (NCT02640729)
  • 19 Jun 2017 Nelotanserin receives Fast Track designation for Lewy body disease [PO,Tablet] (In adolescents, In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top